SLC5A2 and type 2 diabetes mellitus: Articles included in the current meta-analysis if they fulfilled the following inclusion criteria: a) RCT studies assessing the efficacy and safety of SGLT2 inhibitors in patients with CKD and type 2 diabetes and b) Studies with at least six months follow-up period.